Connecting Pharmacology with Therapeutics Clive Roberts.
-
Upload
cameron-pratt -
Category
Documents
-
view
228 -
download
3
Transcript of Connecting Pharmacology with Therapeutics Clive Roberts.
![Page 1: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/1.jpg)
Connecting Pharmacology with Therapeutics
Clive Roberts
![Page 2: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/2.jpg)
Become wise!
![Page 3: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/3.jpg)
![Page 4: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/4.jpg)
![Page 5: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/5.jpg)
![Page 6: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/6.jpg)
![Page 7: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/7.jpg)
What can be predicted from a drug’s pharmacological profile
• Pharmacological actions
• Some adverse effects
• Some contraindications
• Some drug interactions
• Acute toxicity risk
• Mode of administration possibilities
![Page 8: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/8.jpg)
What can NOT be predicted?
• Therapeutic effect
• Appropriate usage in comparison with other drugs
• Some adverse effects
• Some drug interactions
![Page 9: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/9.jpg)
![Page 10: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/10.jpg)
What does the pharmacological profile consist of
• Pharmacodynamic data• Pharmacokinetic data• Physicochemical properties• Potential to induce or inhibit hepatic enzymes• Acute toxicity information• “The therapeutic ratio”• Usage history• Cost
![Page 11: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/11.jpg)
Pharmacodynamic information
• What receptors does it block or stimulate
• Or what ionic channels or enzymes etc does it affect
• What is the hypersensitivity risk
• What unrelated toxicity occurs, how serious and how often
• What happens in acute overdose
![Page 12: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/12.jpg)
Pharmacokinetic information
• How is it cleared from the blood – liver/kidney/lung etc
• First order / zero order process
• If liver, how high is the clearance rate
• What is the bioavailability
• If low is it due to pre-systemic hepatic clearance or poor absorption
![Page 13: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/13.jpg)
![Page 14: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/14.jpg)
![Page 15: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/15.jpg)
![Page 16: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/16.jpg)
![Page 17: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/17.jpg)
Pharmacokinetic info. continued
• How is the drug distributed in the body
• What is the volume of distribution
• What is the extent of plasma protein binding
• What is the plasma half life
![Page 18: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/18.jpg)
![Page 19: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/19.jpg)
![Page 20: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/20.jpg)
![Page 21: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/21.jpg)
Patient groups at risk
• Liver disease
• Renal disease
• Heart disease
• Lung disease
• Elderly
• Those taking other drugs
• Pregnancy
![Page 22: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/22.jpg)
So let’s take the example of
Phenytoin
![Page 23: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/23.jpg)
![Page 24: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/24.jpg)
![Page 25: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/25.jpg)
![Page 26: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/26.jpg)
?? Digoxin
![Page 27: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/27.jpg)
![Page 28: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/28.jpg)
![Page 29: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/29.jpg)
![Page 30: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/30.jpg)
![Page 31: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/31.jpg)
Mrs Y.Y. Born 1912
• Admitted late Feb with general deterioration in health, nausea, anorexia, constipation
• At her EPH there had been an outbreak of D+V 4 weeks previous. She had never really got better.
• Dehydrated, hypotensive, pale, slow reg pulse
![Page 32: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/32.jpg)
• Drugs – perindopril, digoxin, frusemide, aspirin, Isosorbide mononitrate
• Urea 31, creatinine 223
• ECG ……………
![Page 33: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/33.jpg)
![Page 34: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/34.jpg)
• Digoxin level 3.5
• What went wrong?
![Page 35: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/35.jpg)
What is it about the patient with hepatic failure that puts them at
risk• Pharmacokinetic disturbance -
– Decreased clearance of some drugs– Increased bioavailability of some drugs– Altered distribution volume– Decreased protein binding
• CNS sensitivity
• Electrolyte abnormality
![Page 36: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/36.jpg)
What is it about the patient with hepatic failure that puts them at
risk - continued
• Fluid retention
• Risk of bleeding – generally and specifically in gut
• Metabolic disturbance
• Encephalopathy risk
![Page 37: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/37.jpg)
And the renal patient ?
• Pharmacokinetic disturbance – Mainly affecting drug clearance– Also protein binding
• Increased sensitivity
• Poor tolerance of adverse effects
• Decreased effectiveness of some drugs
![Page 38: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/38.jpg)
Drugs in the elderly
• Multiple indications leads to polypharmacy
• Pharmacokinetic disturbance of metabolism, excretion, protein binding and drug distribution
• Increased sensitivity to the actions of drugs on CVS, CNS, GIT
• Poor tolerance of adverse effect
![Page 39: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/39.jpg)
Drug interaction
• Pharmacodynamic mechanisms usually easy to predict
• Pharmacokinetic mechanisms – need to know / look up.
![Page 40: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/40.jpg)
Le Fin
![Page 41: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/41.jpg)
Profile of new drug for reflux oesophagitis
• Phenothiazine drug with powerful antigastric secretory action at low doses.
• Acts on both h2 receptors and the proton pump• Also blocks muscarinic receptors throughout the
body• Inhibits some hepatic enzymes• Causes a rise in transaminases in some patients• Limited experience in overdose
![Page 42: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/42.jpg)
Profile of new drug for reflux oesophagitis
• High hepatic clearance with extraction ratio of 65%
• Widely distributed in tissues
• Plasma half life of 48 h
![Page 43: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/43.jpg)
What might you predict about the adverse effects?
Who might be at greatest risk?What drug interactions might
occur?What about self harm doses?
![Page 44: Connecting Pharmacology with Therapeutics Clive Roberts.](https://reader036.fdocuments.net/reader036/viewer/2022062511/5515e2a1550346cf6f8b4da2/html5/thumbnails/44.jpg)